The bromodomain and extra-terminal domain (BET) proteins are promising drug targets for cancer and immune diseases. However, BET inhibition effects have been studied more in the context of bromodomain-containing protein 4 (BRD4) than BRD2, and the BET protein association to histone H4-hyperacetylated chromatin is not understood at the genome-wide level. Here, we report transcription start site (TSS)-resolution integrative analyses of ChIP-seq and transcriptome profiles in human non-small cell lung cancer (NSCLC) cell line H23. We show that di-acetylation at K5 and K8 of histone H4 (H4K5acK8ac) co-localizes with H3K27ac and BRD2 in the majority of active enhancers and promoters, where BRD2 has a stronger association with H4K5acK8ac than H3K27ac.
side-chain guanidium group of R95 in V L and the main-chain carbonyl group of R98 in V H .
On the other hand, the carbonyl group of the ε -amino group of K8ac is specifically recognized by the main-chain amino groups of D99 and Y100 in V H (Fig. 1d) . The side chain of R98 spatially separates the two Kac-recognizing cavities, and only V H residues form the K8ac-recognizing cavity (Fig. 1d) . Hence, we found that the individual H4K5acand H4K8ac-binding modes of the antibodies are completely different from the cooperative H4K5acK8ac-binding mode of the BRDT BD1 bromodomain reported by Moriniere et al. 22 By comparing the primary and tertiary structures of the two antibodies (Fig. 1e,f and Supplementary Fig. 1c ), we reasoned that A54 of V H in 2A7D9 is responsible for the strict discrimination of H4K5acK8ac. In 1A9D7 composing E54 at the same position, the Fab fragment does not bind to the N-terminal S1 residue of H4 (Fig. 1e) . In contrast, A54 of 2A7D9 has a smaller side chain than that of the glutamic acid (i.e. E54), thus allowing binding of N52 and T53 to S1 of the H4 N-terminal tail (Fig. 1f) . Thus, 2A7D9 preferentially binds to the N-terminal H4 sequence that contains S1 at the -4 position relative to H4K5ac than to any other histone tail peptide sequences (Fig. 1b) . Since 1A9D7 cannot bind to H4S1, it cannot exclude binding to the N-terminal H2B sequence carrying K12ac and K15ac that contains P8 at the -4 position relative to H2B K12ac ( Supplementary Fig. 1c) . Although there are a series of monoclonal antibodies that detect mono-acetylation of histone H4 at K5, K8, K12 and K16, no structurally validated monoclonal antibody recognizing a specific combination of histone tail modifications has been reported before to our knowledge. Hence, our crystallographic analysis provides the structural basis for the selective recognition and validation of H4K5acK8ac by the 2A7D9 antibody.
H4K5acK8ac co-localizes with H3K27ac at active promoters and enhancers
To perform a genome-wide profiling of H4 hyperacetylation and to compare it with other active chromatin marks, we performed ChIP-seq with the 2A7D9 antibody against H4K5acK8ac, along with antibodies for H3K27ac, H3K4me1, and H3K4me3. We identified 22,882 robust H4K5acK8ac peaks (irreproducible discovery rate, IDR < 0.01), of which 34.5% are at the RefSeq promoters, 25.6% at introns and 29.8% at intergenic regions ( Fig. 2a and Supplementary Table 3) . Consistent with the notion of acetylated histone H4 as an open chromatin mark, H4K5acK8ac is found at transcriptionally active or open chromatin regions, including: i) enhancers (overlap with H3K27ac and H3K4me1; Fig. 2b,c) , ii) active enhancers (H3K27ac >5 kb outside TSS; Fig. 2d, top) , iii) active promoters (H3K4me3 5 kb ± from TSS; Fig. 2d, bottom) , and iv) FANTOM5 transcribed enhancers ( Fig. 2e) . The co-localization of H4K5acK8ac with the active promoter and enhancer marks were further confirmed by immunostaining ( Supplementary Fig. 2a ).
Consistently, H4K5acK8ac is associated with actively transcribed promoters and enhancers, as determined by co-localization with CAGE signals (~77% of TSS with expression level ≥ 0.25 CAGE tag per million, TPM) ( Supplementary Table 3 ). Overall, our data show that the H4K5acK8ac mostly occupies active enhancer and promoter regions.
Stronger association between BRD2 and H4K5acK8ac than BRD2 and H3K27ac
Although BET proteins preferentially bind to multi-acetylated histone H4 in vitro (mimicking hyperacetylation), it is not known whether BRD2 preferentially binds to hyperacetylated H4 in vivo, compared to other acetylated forms such as H3K27ac. Since the BRD2 binding pattern in H23 cells has not been characterized yet, we performed BRD2 ChIP-seq and identified 4,647 robust BRD2 binding sites, which are found at promoters (47.5%), introns (21.7%), and at intergenic regions (15.8%) ( Supplementary   Fig. 2b) . Moreover, when overlaid with the CAGE data, 87% of BRD2 sites are localized at actively transcribed promoters of coding and non-coding genes (CAGE ≥ 0.25 TPM, Supplementary Table 3 ). Consistently, BRD2 sites are highly enriched for active marks (e.g., H3K4me3, H3K27ac, and H4K5acK8ac) ( Fig. 2f) , where at least 95% of the BRD2 peaks overlap with H4K5acK8ac and H3K27ac (Fig. 2g) .
In a complementary analysis, we examined the enrichment of bromodomain proteins BRD2, BRD4 and EP300 at the H4K5acK8ac sites using the publicly available ChIP-seq datasets from the closely related cell types: BRD4 ChIP-seq from SCLC cell line H2171 (GSM1038270) 17 and ENCODE P300 ChIP-seq from NSCLC A549 23 . We found that promoter-and enhancer-associated H4K5acK8ac regions were enriched for BRD2, BRD4 and EP300 ( Supplementary Fig. 2c ), suggesting the co-localization of H4K5acK8ac with these bromodomain-containing proteins. We also identified 432 super-enhancers based on H4K5acK8ac peaks, which are also enriched with H3K27ac and BRD2 ( Fig. 2h and Supplementary Table 4 ). Taken together, our ChIP-seq analysis shows that BRD2 mostly localizes to active promoters and enhancers including super-enhancers in H23 cells.
To determine how strongly BRD2 co-occurs with H4K5acK8ac or H3K27ac, we calculated the odds ratio (OR) between BRD2 and each histone modification mark. BRD2 is associated at the strongest level with H4K5acK8ac, followed by H3K27ac and H3K4me3, and at the lowest level with H3K4me1 ( Fig. 3a) . This finding was further verified using an independent analysis where we determined the correlation between BRD2 and H4K5acK8ac or H3K27ac ChIP-seq read intensities within a defined set of active genomic regions. First, we created a reference of 30,243 active genomic regions based on CAGE transcription start sites (unidirectional TSS and bidirectional enhancers), H4K5acK8ac peaks, and H3K27ac peaks. Based on this reference, normalized ChIP-seq read intensities of BRD2 were plotted against those of H4K5acK8ac or H3K27ac (Fig.   3b ). The levels of H4K5acK8ac correlate well with that of BRD2; weak H4K5acK8ac with weak BRD2 and strong H4K5acK8ac with strong BRD2 (Fig. 3b, left) , whereas a small number of the active regions is enriched for strong H3K27ac, but contains much weaker BRD2 signals ( Fig. 3b , right, the top right corner). Thus, BRD2-H4K5acK8ac colocalization shows higher enrichment (Odds Ratio of 62.99) than the BRD2-H3K27ac association (Odds Ratio of 15.32) ( Fig. 3b) . Collectively, our findings uncovered for the first time a strong evidence for the preferential binding of BRD2 to K5/K8-diacetylated histone H4 sites (representing H4-hyperacetylated states) genome-wide.
Identification of a chromatin state with high H4K5acK8ac, low H3K27ac and low BRD2
We next asked whether there are any regions in the genome that are more highly enriched for H4K5acK8ac than H3K27ac (and vice versa), and whether there is any correlation with the BRD2 level. We performed ChromHMM 24 with 5 active histone marks (H4K5acK8ac, H3K4me1, H3K27ac, H3K4me3, and H3K36me3), 2 inactive histone marks (H3K27me3 and H3K9me3), and BRD2. Based on 20 emission states, we successfully recapitulated the known chromatin state patterns ( Fig. 3c and Supplementary Fig. 3a,b) : strong and weak promoters (orange states: 1, 4, 5), enhancer (yellow states 2-3, 6-8, 10-12), transcription (green states: 12-16) as well as heterochromatin (blue states 9, 17-20). The strong promoter states were differentiated into states 4 and 5 by the BRD2 presence (state 5 is BRD2-bound, and state 4 is BRD2-unbound promoters). Of the five strong enhancer states, state 8 'H4K5acK8ac enhancer' is significantly enriched for H4K5acK8ac compared to H3K27ac (Fig. 3d, upper) , whereas state 10 'H3K27ac enhancer' is more significantly enriched for H3K27ac than H4K5acK8ac (Fig. 3d, lower) , both of which are not enriched for BRD2 ( Fig. 3c and Supplementary Fig. 3c ). Additionally, enhancer state 3 contains both H4K5acK8ac and H3K27ac and is moderately enriched with BRD2 ( Fig. 3c ).
Since the H4K5acK8ac or H3K27ac enhancer states have low BRD2 enrichment, we next investigated the presence of other bromodomain proteins, EP300 (from A459) and BRD4 (from SCLCL H2171) at these states ( Fig. 3c) . Although EP300 and BRD4 are enriched in both enhancer states ( Supplementary Fig. 3e ), BRD4 enrichment is much higher in H4K5acK8ac enhancer state than in H3K27ac enhancer state ( Supplementary   Fig. 3e , left and right), again suggesting preferential binding of BRD4 to H4K5acK8ac.
Overall, our analyses suggest that different bromodomain-containing proteins might recognize H4K5acK8ac-or H3K27ac-specific enhancers. Furthermore, although BRD2 has a preferred association to H4K5acK8ac over H3K27ac, it tends to be found at promoters/enhancers that have both H4K5acK8ac and H3K27ac.
BET inhibition by JQ1 does not affect global K5acK8ac level of histone H4
Since BRD2 exhibits a preference to H4K5acK8ac, we sought to elucidate whether inhibition of BET protein binding by JQ1 affects hyperacetylated histone H4 level. To examine this, H23 cells were treated with 500 nM JQ1 for 24 hours followed by "spike-in" ChIP-seq with either BRD2 or H4K5acK8ac antibody (see Methods). Under this condition, BRD2 binding was almost completely depleted at a global level ( Fig. 4a) .
Consistent with the previous studies 5,15 , we did not observe any global changes in H3K27ac level (Supplementary Fig. 4b) . Interestingly, we observed that global H4K5acK8ac levels (including at promoters, enhancers, and super-enhancers) were also not affected by JQ1 (Fig. 4a, middle and right, Fig. 4b,c) . Thus, the inhibition of BET protein binding to chromatin does not significantly change the global hyperacetylation level of histone H4, implying that BET proteins are not required for maintaining or protecting the H4K5acK8ac histone modifications.
Despite the lack of global H4K5acK8ac change, we observed a small subpopulation of H4K5acK8ac peaks (~2%; false discovery rate, FDR ≤ 0.05, 2-fold change) to be sensitive to JQ1 treatment ( Fig. 4d) . Similar changes in H3K27ac levels were also observed at these regions ( Supplementary Fig. 4c,d ) and the changes in the H4K5acK8ac levels correlate significantly with the transcriptional activities of the associated promoters (Fig. 4e) . The increased H4K5acK8ac peaks are associated with promoters, as they are highly enriched for H3K4me3 and to a lesser degree for H3K4me1 ( Fig. 4f) , while the decreased peaks are associated with transcribed enhancers, indicated by CAGE peaks and the high H3K4me1/H3K4me3 ratio ( Fig. 4g) . Interestingly, the H4K5acK8ac-specific regions that are affected by JQ1 are not bound by BRD2, although we cannot exclude BRD4/BRD3 enrichment in these regions ( Fig. 4f,g) .
JQ1 treatment induces apoptosis in a MYC-independent manner in H23 cells
We next asked how the H4K5acK8ac/H3K27ac ratios are associated with transcriptional response to JQ1. We observed that active promoters with higher H4K5acK8ac level tend to be more downregulated upon JQ1 treatment (Fig. 5a , bottom right corner), whereas active promoters with similar levels of H4K5acK8ac/H3K27ac or high H3K27ac show both directions (i.e., upregulated and downregulated), suggesting different regulatory mechanism are acting on these regions.
Differential expression analysis between JQ1-treated cells and DMSO-treated (vehicle control) cells at 3, 6, 12 and 24 hours showed that more genes were downregulated than upregulated (FDR < 0.05 and fold change ≥ 2, Supplementary Fig. 5a and Supplementary Table 5 ). We successfully validated 20 differentially expressed genes by qPCR ( Supplementary Fig. 5b and Supplementary Table 9 ). Consistent with other studies 5,15 , BRD2 and BRD4 expression levels were not reduced by JQ1 treatment (confirmed by qPCR), and similar to other NSCLC cell lines 25 , anti-apoptotic oncogenes CFLAR (FLIP) and BCL2 were markedly downregulated after 3 and 24 hours of JQ1 treatment, respectively ( Supplementary Fig. 5c ). HOXC genes (important for antiapoptotic pathway 26 ) were downregulated at the early time point ( Supplementary Fig. 5d) in line with the number of H23 cells undergoing apoptosis and cell proliferation rate (Fig.   5b ). The main components of canonical Wnt/β-catenin signaling are reported to be modulated by JQ1 5, 27, 28 , and in H23 cells, WNT2, WNT5A, and the mediator of Wnt signaling (LEF1 and TCF genes) were downregulated, while β-catenin encoded by CTNNB1 was only slightly affected ( Supplementary Fig. 5e ). MYC is a Wnt signaling target and a key transcription factor (TF) that is downregulated by JQ1 in MM.1S, leukemia, and breast cancer cells 5, 15, 29 and is believed to mediate JQ1's anti-oncogenic effect. Here we observed the upregulation of MYC expression after JQ1 treatment in H23 cells ( Fig. 5c and Supplementary Table 4 ). This is in agreement with results from another JQ1-sensitive NSCLC cell line 10 , where the effect of JQ1 on the cell growth is thought to be mediated by FOSL1, and not MYC 10 . Notably, we also observed the downregulation of FOSL1 upon JQ1, as confirmed by Western blot and qPCR ( Fig. 5d ).
Potential BRD2-coupled transcription regulatory pathways
To elucidate the regulatory pathways affected by BET inhibition, we carried out pathway analysis upon JQ1 treatment at each time point and determined BRD2 enrichment in these pathways. Specifically, we performed a clustering on the normalized enrichment score (NES) of the enriched pathways (p-value ≤ 0.01, FDR < 0.25) ( Fig. 5e , the complete list of the enriched pathways is available in the Supplementary Table 6 ). Upregulated pathways, such as cell cycle regulation, Wnt/β-catenin signaling target genes, apoptosis pathway, E2F-target genes, RNA processing-related genes, and MYC target genes, were highly enriched for BRD2 binding ( Fig. 5e and Supplementary Fig. 5d,e ). On the other hand, downregulated pathways, such as cytokine-cytokine receptor pathway, G protein signaling, and KRAS target genes, were much less enriched for BRD2 binding ( Fig. 5e and Supplementary Fig. 5d,e ). Differential expression analysis of the BRD2-bound genes also shows similar sets of genes are enriched (FDR < 0.05, log 2 fold change ≤ -1; Supplementary Table 7) , including upregulation of MYC. Furthermore, pathway analysis using multiple functionally validated gene sets confirmed the enrichment of MYC and E2F target gene sets in the upregulated genes (NES ≥ 1.5, FDR ≤ 0.01) ( Supplementary Fig.   5f ).
Identifying TF candidates of BRD2-dependent and independent regulatory pathways
Since JQ1 treatment shows diverse effects (both upregulation and downregulation) on BRD2-bound genes, we hypothesized that different TFs might be involved in the transcriptional regulation in response to JQ1. We first performed Motif Activity Response Analysis (MARA) 30 (Z-value ≥ 2.0) using CAGE data and identified several candidate TFs that are responsible for up-or downregulation of genes upon JQ1 treatment (Z-value ≥ 2.0) ( Fig. 6a and Supplementary Table 8 ). Among them are E2F3 and YY1 that show increased motif activity upon JQ1 treatment, and ZNF281, LEF1, FOSL1 that show decreased motif activity ( Fig. 6a) . To further refine TF candidates into BRD2-dependent or independent pathways, we performed motif search analysis by HOMER 31 using BRD2 binding sites of upregulated and downregulated promoters. The downregulated promoters were enriched in ZNF281 binding motifs ( Fig. 6b, left) , while E2F4 and YY1-binding motifs were enriched in the upregulated promoters ( Fig. 6b, right) . Since LEF1 and FOSL1
were not identified in the downregulated genes, they are likely to be involved in the non-BRD2 regulatory pathway. To investigate this, we performed HOMER 31 motif search and found that LEF1 and FOSL1 binding motifs were enriched within H4K5acK8ac peaks without BRD2 (Fig. 6c, right) . On the other hand, E2F, YY1, and ELK1 motifs were enriched in H4K5acK8ac peaks with BRD2 binding (Fig. 6c, left) . It is of note that previous studies revealed interaction of BRD2 with CTCF 32,33 . Our HOMER motif enrichment analysis also shows higher enrichment of CTCF motif in the downregulated genes ( Supplementary Fig. 6a ) and the CTCF binding sites (from A549 cells) are more enriched in the BRD2 peaks associated with the downregulated genes than upregulated genes ( Supplementary Fig. 6b ). Taken together, our findings provide a possible model where BRD2 recruits TFs such as YY1, E2F4, CTCF, and ZFN281 and regulate these genes, and other TFs such as LEF1 and FOSL1 are recruited to non-BRD2 BET proteins.
DISCUSSION
Antibody quality in terms of target specificity and reproducibility is one of emerging issues in the biological sciences 34, 35 . In this study, we generated monoclonal antibody that specifically detects di-acetylation at K5 and K8 of histone H4, a hallmark of H4hyperacetylated chromatin states in vivo. Peptide array and crystal structure analyses confirmed its exclusive binding to H4K5acK8ac. By applying the structurally validated antibody to ChIP-seq, we demonstrate that BRD2 preferentially associates with H4K5acK8ac genome-wide. We showed that the reduced binding of BRD2 by JQ1 did not affect the global H4K5acK8ac level at the BRD2 sites. We further identified active enhancer states containing significantly different enrichment between H4K5acK8ac and H3K27ac. By separately analyzing the differentially expressed regions that are bound or not bound by BRD2 prior to the JQ1 treatment, we identified several TF candidates that may be involved in the regulation of BRD2 and non-BRD2 target genes.
The finding that H4K5acK8ac levels at BRD2 binding sites were not affected despite complete reduction of BRD2 after JQ1 was surprising. In LPS-activated macrophages, BET inhibition reduced the levels of H3ac, H4K5ac, H4K8ac, H4K12ac and total H4ac on promoter of the induced genes 36 . This reduction is presumably due to increased accessibility of HDAC to the exposed BET sites by preventing the formation of multimolecular complexes containing HATs and other transcription machineries 36 , as shown by the reduced level of positive transcription elongation factor b (P-TEFb/CDK9) and RNA polymerase II on the affected regions 36 . In H23 cells, however, a subset of BRD2-bound genes involved in RNA processing such as POL2RA and CDK9 was in fact upregulated, and the transcription levels of HATs, such as KAT2A and EP300, were not affected by JQ1. This indicates that HAT-containing transcription complexes can still be recruited upon JQ1 treatment, and H4-hyperacetylated states could be maintained through the HAT activities of these complexes even if BET proteins are off the chromatin.
Several JQ1 studies have been conducted in NSCLC cell lines 10, 19 , however, our study delivers more comprehensive transcriptome data by using CAGE, with which we identified downregulation of cytokine-cytokine receptor interaction pathways and several regulators of tumor-associated inflammation, such as IL6, which were not reported before. These findings are consistent with the previous reports that JQ1 inhibits inflammation in pancreatic ductal adenocarcinoma 37 and a murine periodontitis model 38 . Thus, our study implicates that JQ1 might also reduce inflammation in NSCLC cells.
Although MYC is downregulated in many cell types upon JQ1 treatment and thought to be the key mediator of JQ1 effects, our study together with the previous study 10 suggests that H23 cells exhibit MYC-independent response to JQ1. Supporting the previous study that proposed FOSL1-dependent mechanism 10 in response to JQ1, our study suggests FOSL1 and LEF1 might regulate transcription of non-BRD2 target genes (quite possibly through BRD3 and/or BRD4). This result is consistent with the previous report that LEF1 acts as a coactivator in the presence of EP300 39 and induces lung adenocarcinoma metastasis 40 , while FOSL1 controls gene expression program mediating metastasis 41 . Since . In our study, the expression of YY1 and E2F4 were not affected by JQ1. Thus, they may still bind to their target genes and recruit other coactivators that lead to up-regulation of their target genes. Since ZNF281 is involved in the control of epithelial-mesenchymal transition (EMT) and promotes metastatis 46 , anti-oncogenic effects of JQ1 on H23 cells may partly be due to downregulation of ZNF281, which may lead to apoptosis. Further analyses, such as identification of their target genes by ChIP-seq, knockdown experiments of the TFs and immunoprecipitation of BRD2 protein complex would elucidate the roles of these TFs.
Collectively, we shed lights on the mechanism of BET inhibition effects at the H4-13 hyperacetylated chromatin and transcriptome levels in H23 cells. The complexity of BET inhibition effects becomes increasingly evident, and it can be explained by future comparative analyses among BET family members, cell types, and epigenetics-regulating agents. In particular, our study reveals that BET inhibitors such as JQ1 may only be effective temporarily as anti-cancer progression, since they may not have the potency to change the epigenomic state of H4 hyperacetylation by monotherapy. It would, therefore, be interesting to investigate the synergistic effects of BET and HAT inhibitors on chromatic histone acetylations, especially on H4 hyperacetylation.
METHODS
Methods and associated references are available in the supplementary file. 
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The authors declare no competing financial interests. Transcription factor-binding motifs within the BRD2 peaks that overlap the downregulated (right) or the upregulated genes (left). The motifs were found de novo by HOMER and then linked to the best matching known motifs. The occurrence panels represent the enrichment of the motif within 6 kb +/-from the peak summit in BRD2 peaks at the downregulated (orange) and upregulated (green) genes. (c) LEF1 and FOSL1-binding motifs enriched in H4K5acK8ac peaks without BRD2 (right) and E2F, ELK1, YY1 binding motifs enriched in the BRD2-H4K5acK8ac peaks (left).
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